Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Below is an exerpt from the actual clinical study of the device they reference in the Tweet.
Reduced pain. Faster healing.
What's not to like about it?
Results: Pulsed electromagnetic fields produced a 57 percent decrease in mean pain scores at 1 hour (p < 0.01) and a 300 percent decrease at 5 hours (p < 0.001), persisting to 48 hours postoperatively in the active versus the control group, along with a concomitant 2.2-fold reduction in narcotic use in active patients (p = 0.002). Mean IL-1ß concentration in the wound exudates of treated patients was 275 percent lower (p < 0.001). There were no significant differences found for tumor necrosis factor-a, vascular endothelial growth factor, or fibroblast growth factor-2 concentrations.
Conclusions: Pulsed electromagnetic field therapy significantly reduced postoperative pain and narcotic use in the immediate postoperative period. The reduction of IL-1ß in the wound exudate supports a mechanism that may involve manipulation of the dynamics of endogenous IL-1ß in the wound bed by means of a pulsed electromagnetic field effect on nitric oxide signaling, which could impact the speed and quality of wound repair.
Looks like they are starting to market the Sofpulse (Twitter update).
The next PR "update" will hopefully be heart news.
Then after that will be FDA registration completion to start clinical trials of Theracap.
Around the same time of this should be clinical trial of tPEMF to treat ischemic stroke.
Then we should be be due for some pre-clinical results of the other organs and conditions being treated with Immunotronics.
I wonder if they are gearing up for a new trial with an updated device? Or are they just advertising what they have and what it has been used for already.
Here is a link to the clinical trial.
https://clinicaltrials.gov/ct2/show/results/NCT01262599?term=PEMF&cond=Breast&rank=1
Good to see they are at least using Twitter to market themselves.
I don't understand how they can sit on that patent. Find a partner to assist with the research and marketability of the technology!!
Endonovo has also talked about MS research using Rio Grande's technology.
Here is the link for the patent filed by RGN:
https://www.google.com/patents/WO2016134367A1?cl=en
Although various PEMF studies in MS demonstrate positive outcomes overall, they have somewhat varied outcomes individually, which could be due to the specific device, the study design, sample size (e.g., more subjects may statistically demonstrate subtler effects), treatment duration, type of MS, medication history, etc.
Let's hope our patent becomes more of the defacto standard for MS treatment.
This is more of a longer term potential catalyst for the company.
I could not find any direct link of the money from the NFL going towards Spaulding Rehabilition Hospital (where the RGN clinical trial was to be performed).
But I did see that Dr. Ross Zafonte who was going to oversee the clinical trial, in the past, has been funded by NIH (who is receiving a the bulk of the money from NFL) and Dept. of Defense (which also is receiving some NFL money). The DOD money portion of the NFL $ seems to be going to 30 Universities and appears to be more for monitoring and collecting data.
Here is a tidbit about Sofpulse a few years ago.
Pulsed electromagnetic fields (PEMF) have been demonstrated to have anti-inflammatory and pro-regenerative effects in animals and humans. We used the FDA-approved Sofpulse™ (Ivivi Health Sciences, LLC) to study effect of PEMF on infarct size and poststroke inflammation following distal middle cerebral artery occlusion (dMCAO) in mice. Electromagnetic field was applied within 30-45 min after ischemic brain damage and utilized twice a day for 21 consecutive days. Ischemic infarct size was assessed using MRI and histological analysis. At 21 days after dMCAO, the infarct size was significantly (by 26 %) smaller in PEMF-treated animals as compared to controls. Neuroinflammation in these animals was evaluated using specialized cytokine/chemokine PCR array. We demonstrate that PEMF significantly influenced expression profile of pro- and anti-inflammatory factors in the hemisphere ipsilateral to ischemic damage. Importantly, expression of gene encoding major pro-inflammatory cytokine IL-1a was significantly reduced, while expression of major anti-inflammatory IL-10 was significantly increased. PEMF application significantly downregulated genes encoding members of the major pro-apoptotic tumor necrosis factor (TNF) superfamily indicating that the treatment could have both anti-inflammatory and anti-apoptotic effects. Both reduction of infarct size and influence on neuroinflammation could have a potentially important positive impact on the poststroke recovery process, implicating PEMF as a possible adjunctive therapy for stroke patients.
Effect of Pulsed Electromagnetic Field (PEMF) on Infarct Size and Inflammation After Cerebral Ischemia in Mice. Available from: https://www.researchgate.net/publication/260252858_Effect_of_Pulsed_Electromagnetic_Field_PEMF_on_Infarct_Size_and_Inflammation_After_Cerebral_Ischemia_in_Mice
Doing some DD on concussion and PEMF.
What is there not to like about reduction of symptoms AND NO adverse effects?
https://www.drpawluk.com/blog/concussion-and-tbi/
Summary bits from the link above.
Evidence now also tells us that pulsed electromagnetic field therapies can help with, not only the injury itself, but also many of the symptoms resulting from it. In other words, PEMFs are not only useful for symptom management in the person suffering from TBI/concussion, but also have the opportunity to actually heal the brain to reverse the long-term effects of brain damage.
It appears that even very high intensity PEMFs used for extended periods of time produce virtually no adverse effects on the brain and may even decrease the risk of future cancer development and the development of Alzheimer’s/dementia.
Because of the lack of risk seen with the use of TBI, PEMFs should be a routine therapeutic approach in the management of mild to moderate TBI and concussion, and potentially greatly supportive to other adaptive therapies in accelerating recovery and function.
There is much evidence to suggest that there is minimal risk, The safety and risk of PEMFs have been assessed in a number of studies
Frank is the securities lawyer acting as the authorized representative of ENDV for the offering. This is not stating he purchased the $700k portion of the offering.
Section 14 shows there are 13 investors that have been involved as part of the $700k up to that date.
Here is a link about the clinical trial of the Theracap in 2015-2016.
https://clinicaltrials.gov/ct2/show/NCT02643836
Endonovo is focusing on concussion research.
NFL has stepped up their efforts in concussion research.
New PR from NFL
http://www.nfl.com/news/story/0ap3000000903014/article/nfl-announces-grants-toward-advancement-of-neuroscience
With the marketing reach of the NFL, would be HUGE news if our technology becomes the remedy to assist with the healing of concussions.
Thanks for the info. I can sleep better at night knowing ENDV will play it smart with the financing.
They need to attend this conference:
https://www.bio.org/events/bio-ceo-investor-conference
BIO CEO & Investor Conference
The BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies. Because our mission is to support industry-wide success, we present a broad and unbiased view of investment opportunities.
Feb 12 - 13
I just sold. Needed the $ for a BIO play next week.
Good luck to you.
I was wondering if ENDV would do anything with the Traumatic Brain Injury Conference May 16-17.
Might be too early.
Even if ENDV does not have results, they should be attending these conferences and networking. Get the ENDV name out there.
The good thing at this low SP, we are averaging 3m shares dilution each week.
Based on 187m remaining to reach 500m A/S, we have 62 weeks to max out if we remained at this share price.
No way we remain at this low level for much longer. I think we are safe from maxing out any time soon.
My concern is if the company does a R/S as a shortcut to get uplisted faster. I don't know if we'll be able to reach and sustain the required SP to be uplisted on our own merit. We can't seem to gain on good news lately.
O/S shares as of this AM
312,756,585
Hola.
Taking a ride with you here also.
I have a small position from 9.65.
And I want to see the winning result of our bet <grin>
Do you think this acquisition might be causing delay with the further advancement of the heart study?
Why would ENDV post in a PR they will submit results @ a scientific meeting in 2018 and not say what the next stage of testing will be or any mention of working under FDA clinical testing guidelines for FDA approval as the next catalyst? They want to get peer opinions and suggestions before the next stage of testing?
I wonder if the CNS disorder study is becoming the primary focus since it is further along? Do you know exactly what stage of study the CNS disorder is at? I believe you mentioned it is in final clinical stage (at least past pre-clinical)?
Any estimate of timeframe for this study to be completed for final review?
Look at that. It is happening a day or 2 after I said the Fed could ruin things the state have set up.
I have not read the news but have heard comments from casual talk today.
ENDV is the secure investment.
Everyone wants better health!!!
You won't find the Gov't trying to block devices that will make people well/healthy.
We need to stop looking at L2. It's driving us crazy. That's why I've been trying to create other conversations based on the new stuff we have.
Doesn't seem to be working...hehe.
I've brought up things about Sofpulse...who wants to take the reins and give info and updates on the concussion study?
Speaking of We Heal Animals....look at this video. Do you think this device is infringing on our Sofpulse patent?
ENDV was in talks for many months with RGN.
There was a RGN PR back in March 2017.
This PR was about RGN trying to sell their assets and technology.
"The company has been in discussion with another party that has expressed an interest in acquiring the Company’s PEMF and TES assets and so has decided not to offer them for sale. The Company had previously expressed a desire to sell all three assets but withdrew the offer both because baseless claims were made that another entity had a prior right to buy the Company and of the pendency of an offer from a legitimate buyer to purchase all the the assets. The entity claiming to have a prior right to purchase the Company has withdrawn that claim, and the pending offer to purchase has narrowed to PEMF and TES."
I would love for your theory to be right, but I believe it will not come to reality in the near term, if at all.
I believe ENDV has been stopping the work with Cytotronics and stem cells. They still might be working on something small scale in the background but all signs point to a temporary stoppage.
Working with stem cells is a very slow and long testing process. It is most likely an expensive one at that also. I think ENDV is focusing on the revenue producing assets (RGN) and Immunotronics for now.
What happened to the PR of hiring attorneys to get the orphan drug designation? It must have failed and ENDV is keeping it swept under the rug?
What happened to the hyped GVHD testing?
I think ENDV thought Immunotronics would be faster to bring to the market and focused on that.
I would love for ENDV to pull a Cytotronics update out of their rabbit hat and say "surprise". I just don't think that will happen.
Have you noticed they don't even mention stem cell research anymore in their company summary in the latest PRs?
Endonovo only acquired some assets from RGN rather than purchasing the entire company. The original plan was to purchase the company outright. That is why there is a big monetary difference of acquisition this time around.
RGN is looking for a buyer of their other technologies. Also as Biotech mentioned, there is a penalty against RGN involved for breaking the binding letter of agreement.
We may have a difference of opinion, but that is why we have this board for open discussion.
I may have countered your theory, but I hope you are right for all of the long holders that originally bought into the Cytotronics hype.
Did a little history investigation of Sofpulse.
Aug. 1998 - ADM Tronics acquires Sofpulse assets.
April 2005 - Ivivi (a subsidiary of ADM) introduces the next generation of Sofpulse (New and improved version).
Dec. 2008 - FDA gives clearance to Ivivi for 3 models of Sofpulse.
Sep. 2009 - Ivivi sells some assets to Steve Gluckstern (CEO of Rio Grande..although RGN is not mentioned in PR). The assets are not specifically mentioned but this creates business relationship between the companies.
SEP 2015 - Rio Grande acquires Ivivi's tPEMF technology. RGN was previously licensing the use of it.
Seems ADM Tronics is doing the manufacturing and logistics of the device.
This device has been around in it's current FDA approved form since end of 2008?
Has it been a victim of mismanagement?
I can understand Ivivi's challenge of handling it during the financial crisis of 2007-2008 and then the delay of FDA approval.
What is Rio Grande's excuse for sitting on it during the years afterwards? That's a long time to sit on a FDA approved device.
Let's see if Endonovo can market a FDA approved device that is years old and never created a big buzz in the medical community.
I did see an article from Aetna (believe dated April 2017) stating they are aware of the device but it has a lack of published data on it's effectiveness.
Endonovo...are you reading this?
Learn from past mistakes.
New Form 4 is out. No missed trading days. Continuous buying by Mann.
I hope it will be like a true rocket and not like a failed North Korean missle <grin>
Hope so. MBOT is my biggest holding at the moment.
They sent out a tweet. People speculating big news coming soon
Ouch. Sorry for your loss with Ivivi. Sofpulse has returned to your portfolio once again. Hopefully it will make up for the bad past experience .... with interest.
The 2 signals work in different ways. Cannot use 1 as a blanket for all ailments.
In my opinion, if/when the heart clinical results produce FDA approval, that will be the major boost for ENDV.
The Softpulse has been out in the market for a while. It has not created a major buzz in the medical field so far. Is it looked upon as a gimmick by medical professionals? Hopefully ENDV can market it better.
Ok....hence why ENDV is now moving to the tPEMF terminology.
Hopefully they will keep the Immunotronics label for the organ studies. I see they did leave out the Immunotronics term in their latest PRs in the About Endonovo section.
It has become a little confusing with the various TVEMF, PEMF, and tPEMF.
As can be seen from the section of About Endonovo on their new PRs....
"The Company's non-invasive electroceuticals use targeted-Pulsed Electromagnetic Fields (tPEMF) to induce micro-currents in tissues to target proinflammatory, fibrogenic and regenerative signaling pathways for the treatment of cardiovascular and cerebrovascular diseases, as well as for the treatment of chronic kidney and liver disease. "
tPEMF appears to be their new acronym to cover all testing (using TVEMF and/or PEMF)
The TVEMF is their patented square wave signal to be used on the organ clinicals and the PEMF signal is what is used with the Softpulse and Theracap devices.
ENDV should see revenue immediately from Softpulse. It is already on the market. We just don't know how the marketing was done with this device before and if Drs. are on board to recommend it to patients.
It is my understanding that the Theracap should also hit the market sometime this year. There is clinical testing in process right now.
I see there is a Sofpulse knockoff for animals called the Assissi Loop.
ENDV should reactivate We Heal Animals and market a Sofpulse equivalent for animals as well.
They have a good donaim reserved for it.
www.wehealanimals.com
You could be right.
I did some more research on Sofpulse this AM. I did not know It has been marketed for years now.
I see it was originally created by Ivivi around 2008. Ivivi was operated by the now owner of Rio Grande.
The device is now being sold and distributed by ADM Tronics Unlimited in NJ.
My original statement was based on the verbage of ENDV PR when they acquired RGN assets.
I believe we need to wait until ENDV is registered with the FDA as the new owner of this technology.
Bitcoin could potentially be a bubble waiting to burst.
Marijuana is interesting but could the US Federal Gov't one day try to put the brakes on what the states are passing?
ENDV, on the other hand, is working on making people healthy. What is there not to like with that?
Low risk. High reward.
Our CEO (in 2016) has said "only 10 percent of drugs entering Phase I trials actually make it to market translating into large financial losses for the pharmaceutical industry."
".....over 40 percent of marketing candidate drugs being terminated as a result of unexpected toxic effects, particularly in the liver."
Yet those drug companies have share prices higher than ENDV.
(shaking my head).
And we are working on a technology to help repair damaged livers.
Wake up BIO investors.
Are you too distracted with fancy gifts and toys from the Pharma companies?
This will help explain what you are seeing.
https://www.google.com/amp/s/incrediblepennystocks.wordpress.com/2013/06/25/incredible-penny-stocks-what-is-a-form-t-trade/amp/
"Unlike pharmaceutical-based treatments, the blood-brain-barrier cannot hinder the delivery of the Company's tPEMF therapy to the brain parenchyma, which is one of the major hurdles to the effective treatment of CNS disorders."
We have a technology that works potentially better than pharmaceutical pills, less risk of side effects, a technology that can be utilized on VARIOUS ailments, and we cannot even stay above $.07???
What the hell is going on here?
How can ENDV share price lag so far behind any pharmaceutical company that focuses only on 1 drug and will take years to go through 3 phases of testing?
Is it due to being on OTC?
Yes, I know ENDV has more O/S, but if you equate the O/S and share price equivalent to other Pharmas, we should be higher.
Maybe ENDV needs investment assistance from a BIG name company/person to show confidence in the technology.
Maybe Mann is trying his hardest to keep it low to accumulate as much as he can.